Oncology

Showing 15 posts of 308 posts found.

Takeda and ImmunoGen collaborate for development and commercialisation of Elahere in Japan

August 29, 2023
Sales and Marketing Elahere, Immunogen, Oncology, Takeda

ImmunoGen has announced that it has entered into an exclusive collaboration with Takeda Pharmaceutical Company for the development and commercialisation …

volodymyr-hryshchenko-m1hq4ibp9rc-unsplash

Janssen submits sNDA to FDA for full approval of Balversa

August 29, 2023
Research and Development Balversa, FDA, Janssen, Oncology

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the submission of a supplemental New Drug Application (sNDA) to …

Lynparza granted approval to treat prostate cancer in Japan

August 25, 2023
Research and Development Merck, Oncology, astra zeneca, prostate cancer

AstraZeneca and Merck (known as MSD outside the US and Canada) have received approval from the Japanese Ministry of Health, …

hal-gatewood-_jbclosdsd4-unsplash

FDA grants ODD to NXC-201 as multiple myeloma treatment

August 24, 2023
Medical Communications FDA, Nexcella, ODD, Oncology, multiple myeloma

Nexcella has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to NXC-201 for …

lungs

Daiichi Sankyo’s Enhertu approved in Japan as treatment for metastatic NSCLC

August 23, 2023
Medical Communications Daiichi Sankyo, Enhertu, Japan's MHLW, NSCLC, Oncology, trastuzumab deruxtecan

Daiichi Sankyo has announced that Enhertu (trastuzumab deruxtecan) has been approved in Japan for the treatment of adult patients with …

Eli Lilly shares topline results from LIBRETTO-531 trial for Retevmo

August 23, 2023
Research and Development Eli Lilly, Oncology, Retevmo, clinical trial, slpercatinib, thyroid cancer

Eli Lilly has announced topline results from the LIBRETTO-531 study assessing Retevmo (selpercatinib) as an initial treatment for patients with …

Merck announces phase 3 LITESPARK-005 trial met primary endpoint

August 22, 2023
Research and Development Merck, Oncology, Welireg, belzutifan, clinical trial, renal cell carcinoma

Merck (known as MSD outside of the US and Canada) has shared topline results from its phase 3 LITESPARK-005 trial, …

FDA grants accelerated approval to Pfizer’s Elrexfio

August 15, 2023
Medical Communications Elrexfio, FDA, Oncology, Pfizer, accelerated approval

Pfizer has that the US Food and Drug Administration (FDA) has granted accelerated approval to Elrexfio (elranatamab-bcmm) for the treatment …

lungs

FDA grants orphan drug designation to Genprex’s Reqorsa

August 15, 2023
Medical Communications FDA, ODD, Oncology, Reqorsa

Gene therapy company Genprex has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) …

NICE shares draft guidance for AI’s use in radiotherapy treatment planning

August 14, 2023
Research and Development AI, Draft Guidance, NICE, Oncology, radiotherapy

The National Institute for Health and Care Excellence (NICE) has shared draft guidance surrounding nine artificial intelligence (AI) technologies which …

FDA approved Janssen’s Akeega for prostate cancer treatment

August 14, 2023
Research and Development Akeega, FDA, J&J, Janssen, Oncology, prostate cancer

The Janssen Pharmaceutical companies of Johnson & Johnson have announced that the US Food and Drug Administration (FDA) has approved …

Zumutor’s cancer drug trial cleared by FDA

August 14, 2023
Research and Development Cancer, Oncology, clinical trial, pharmaceutical

On 11 August 2023, the biopharmaceutical company Zumutor Biologics announced that the trial of its ZM008 drug for cancer had …

pawel-czerwinski-2y8ol_obs1i-unsplash_2

FDA approves Talvey for the treatment of heavily pretreated multiple myeloma

August 11, 2023
Medical Communications FDA, J&J, Janssen, Oncology, Talvey, multiple myeloma

The Janssen Pharmaceutical companies of Johnson & Johnson has announced that the US Food and Drug Administration (FDA) has granted …

towfiqu-barbhuiya-ssz6x-gao0c-unsplash

Sosei Heptares and Cancer Research UK announce first patient dosed in phase 1/2a trial

August 10, 2023
Research and Development Cancer Research UK, Oncology, Sosei Heptares, clinical trial, immunology

Sosei Heptares and Cancer Research UK have announced that the first patient has been dosed in their phase 1/2a clinical …

Sunbird Bio and Glympse Bio merge for development of protein-based diagnostic technology

August 10, 2023
Business Services Glympse Bio, Oncology, Sunbird Bio, merger, oncology

Sunbird Bio has announced that it has completed a merger with Glympse Bio, intending to accelerate the development of both …

The Gateway to Local Adoption Series

Latest content